iBio, Inc. Submits Matters to Security Holders
Ticker: IBIO · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1420720
| Field | Detail |
|---|---|
| Company | Ibio, Inc. (IBIO) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
iBio shareholders voted on something important, details to follow.
AI Summary
On November 20, 2025, iBio, Inc. filed an 8-K report to announce that it submitted matters to a vote of its security holders. The filing does not specify the nature of the matters or the outcome of the vote.
Why It Matters
This filing indicates that iBio, Inc. is engaging its shareholders on important corporate decisions, which could impact the company's future direction and shareholder value.
Risk Assessment
Risk Level: medium — The filing is a procedural update regarding a shareholder vote, but the lack of detail on the matters voted upon introduces uncertainty.
Key Players & Entities
- iBio, Inc. (company) — Registrant
- November 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific matters were submitted for a vote by iBio, Inc. security holders?
The filing does not specify the exact matters that were submitted for a vote by iBio, Inc. security holders.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 20, 2025.
What is the state of incorporation for iBio, Inc.?
iBio, Inc. is incorporated in Delaware.
Where are iBio, Inc.'s principal executive offices located?
iBio, Inc.'s principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California.
What is the purpose of this 8-K filing?
The purpose of this 8-K filing is to report the submission of matters to a vote of security holders by iBio, Inc.
Filing Stats: 754 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2025-11-21 08:09:17
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq S
Filing Documents
- tm2531903d1_8k.htm (8-K) — 36KB
- 0001104659-25-114800.txt ( ) — 199KB
- ibio-20251120.xsd (EX-101.SCH) — 3KB
- ibio-20251120_lab.xml (EX-101.LAB) — 33KB
- ibio-20251120_pre.xml (EX-101.PRE) — 22KB
- tm2531903d1_8k_htm.xml (XML) — 4KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On November 20, 2025, iBio, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on four (4) proposals and cast their votes as described below. A total of 10,566,364 shares were represented in person or by proxy, which represented a quorum. The matters below are described in detail in the Company's definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement"), which was filed with the Securities and Exchange Commission (the "Commission") on October 6, 2025. Proposal 1 – Election of Directors The following two (2) nominees were elected as Class II directors of the Company's Board of Directors (the "Board"), each to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, with the following votes: Name of Director Votes For Withheld Broker Non-Votes 1. Dr. Martin Brenner 4,803,078 75,618 5,687,668 2. Dr. Alexandra Kropotova 2,916,804 1,961,892 5,687,668 Proposal 2 – Auditor Ratification Proposal The stockholders ratified the appointment of Grassi & Co., CPAs, P.C. as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026 based on the votes set forth below: Votes For Votes Against Abstentions Broker Non-Votes 9,912,837 594,576 58,951 0 Proposal 3 - Advisory Vote on the Approval of Executive Compensation The stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers ("say-on-pay"), as disclosed in the Definitive Proxy Votes For Votes Against Abstentions Broker Non-Votes 4,392,583 403,278 82,835 5,687,668 Proposal 4 - Advisory Vote Regarding the Frequency of Future Advisory
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 21, 2025 IBIO, INC. By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: Chief Legal Officer and Corporate Secretary